WGS · GeneDx Holdings Corp. · Webcasts, Transcripts & Audio
$52.37
+0.50 (+0.96%)
At close · Nov 13
Return incl. dividend (before tax)
Play latest call
Q3 2026 earnings call transcript
Market Cap
$1.57B
Shares
29.97M
Volume · Nov 13
1.12M
Avg daily vol (3M)
804.77K
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
GeneDx Holdings Corp. Webcasts
Earnings calls, investor updates, investor days and conferences for GeneDx Holdings Corp. (WGS), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Pull transcripts and briefs through the earnings call transcript API or MCP →
Add these events to your calendar (.ics)
Earnings call
FY26 · Q3
2026-11-09
GeneDx Holdings Corp. (WGS) Q3 2026 Earnings Call Transcript
Positive tone
PAMA reimbursement exposure
Revenue cycle management transformation
Profitable growth and unit economics
Revenue
$123.10M
▲ 5.4% YoY Diluted EPS
$-0.41
Gross margin
69.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-09-08
GeneDx Holdings Corp. (WGS) September 8, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-08-11
GeneDx Holdings Corp. (WGS) August 11, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q2
2026-08-03
GeneDx Holdings Corp. (WGS) Q2 2026 Earnings Call Transcript
Confident tone
Mix management (exome vs genome)
Volume growth and test record
Collections and revenue cycle management
Revenue
$114.44M
▲ 11.4% YoY Diluted EPS
$-0.60
▼ 266.7% YoY Gross margin
68.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-06-09
GeneDx Holdings Corp. (WGS) June 9, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-05-04
GeneDx Holdings Corp. (WGS) Q1 2026 Earnings Call Transcript
Balanced tone
Product Mix Shift to Genome
Exome and Genome Volume Growth
Reimbursement Dynamics and ARR
Revenue
$102.25M
▲ 17.4% YoY Diluted EPS
$-2.16
Gross margin
66.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-03-11
GeneDx Holdings Corp. (WGS) March 11, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-03-02
GeneDx Holdings Corp. (WGS) March 2, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY25 · Q4
2026-02-23
GeneDx Holdings Corp. (WGS) Q4 2025 Earnings Call Transcript
Confident tone
Revenue growth and exome/genome momentum
Sales force expansion into new and existing markets
GeneDxInfinity data set and competitive moat
Revenue
$120.99M*
▲ 26.5% YoY Gross margin
69.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-10-28
GeneDx Holdings Corp. (WGS) Q3 2025 Earnings Call Transcript
Confident tone
Pediatrician market expansion and sales force build-out
Revenue growth and guidance raise
NICU and inpatient growth
Revenue
$116.74M
▲ 51.9% YoY Diluted EPS
$-0.27
Gross margin
72.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-07-29
GeneDx Holdings Corp. (WGS) Q2 2025 Earnings Call Transcript
Confident tone
NICU expansion opportunity
State Medicaid coverage and policy landscape
Customer experience for non-specialists
Revenue
$102.69M
▲ 45.6% YoY Diluted EPS
$0.36
Gross margin
69.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-04-30
GeneDx Holdings Corp. (WGS) Q1 2025 Earnings Call Transcript
Confident tone
Exome and genome market leadership
NICU and inpatient opportunity
Fabric Genomics acquisition
Revenue
$87.11M
▲ 39.6% YoY Diluted EPS
$-0.23
Gross margin
67.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-02-18
GeneDx Holdings Corp. (WGS) Q4 2024 Earnings Call Transcript
Confident tone
Exome and Genome Market Leadership
NICU and UltraRapid Genome Launch
Epic Aura Integration and Customer Experience
Revenue
$95.64M*
▲ 66.6% YoY Gross margin
69.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-10-29
GeneDx Holdings Corp. (WGS) Q3 2024 Earnings Call Transcript
Confident tone
Exome and genome market leadership
Profitability and financial discipline
Genomic newborn screening
Revenue
$76.87M
▲ 44.2% YoY Diluted EPS
$-0.31
Gross margin
62.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-07-30
GeneDx Holdings Corp. (WGS) Q2 2024 Earnings Call Transcript
Confident tone
Margin expansion and cost per test reduction
Exome and genome product mix shift
Cash burn reduction and path to profitability
Revenue
$70.51M
▲ 44.8% YoY Diluted EPS
$-1.10
Gross margin
60.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-04-29
GeneDx Holdings Corp. (WGS) Q1 2024 Earnings Call Transcript
Confident tone
Commercial execution and sales force
Reimbursement and payer coverage
Exome and genome product mix
Revenue
$62.42M
▲ 44.7% YoY Diluted EPS
$-0.78
Gross margin
59.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-02-20
GeneDx Holdings Corp. (WGS) Q4 2023 Earnings Call Transcript
Confident tone
Exome and genome growth
Gross margin expansion
Cash burn reduction and path to profitability
Revenue
$57.42M*
▼ 6.4% YoY Gross margin
53.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-10-30
GeneDx Holdings Corp. (WGS) Q3 2023 Earnings Call Transcript
Revenue
$53.30M
▼ 36% YoY Diluted EPS
$-1.64
Gross margin
47.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-08
GeneDx Holdings Corp. (WGS) Q2 2023 Earnings Call Transcript
Revenue
$48.71M
▲ 34.7% YoY Diluted EPS
$-1.84
Gross margin
38.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-09
GeneDx Holdings Corp. (WGS) Q1 2023 Earnings Call Transcript
Revenue
$43.14M
▼ 20% YoY Diluted EPS
$-3.04
Gross margin
35.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-03-14
GeneDx Holdings Corp. (WGS) Q4 2022 Earnings Call Transcript
Revenue
$61.35M*
▲ 6.1% YoY Gross margin
-26.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-14
GeneDx Holdings Corp. (WGS) Q3 2022 Earnings Call Transcript
Revenue
$83.23M
▲ 92.8% YoY Diluted EPS
$-6.72
▼ 227.3% YoY Gross margin
16.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-15
GeneDx Holdings Corp. (WGS) Q2 2022 Earnings Call Transcript
Revenue
$36.17M
▼ 23.1% YoY Diluted EPS
$-8.38
Gross margin
-81.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-12
GeneDx Holdings Corp. (WGS) Q1 2022 Earnings Call Transcript
Revenue
$53.94M
▼ 16% YoY Diluted EPS
$-10.38
Gross margin
10.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-03-14
GeneDx Holdings Corp. (WGS) Q4 2021 Earnings Call Transcript
Revenue
$57.80M
▼ 9.6% YoY Gross margin
-4.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-15
GeneDx Holdings Corp. (WGS) Q3 2021 Earnings Call Transcript
Revenue
$43.18M
▲ 11.8% YoY Diluted EPS
$5.28
Gross margin
-19.2%
Rev · 7q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-16
GeneDx Holdings Corp. (WGS) Q2 2021 Earnings Call Transcript
Revenue
$47.02M
▲ 56.2% YoY Diluted EPS
$-1384.02
Gross margin
-2.5%
Rev · 6q
Audio
Transcript
Slides
8-K10-Q
Showing 1–27 of 27 webcasts
Key facts
CIK
1818331
CUSIP
81663L200
13F (30d)
171 filings
144 filers
Visit website
Investor relations